Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Formerly Virax Holdings Limited (VHL), 12/12/2014.
|29 Nov 2021||$0.21||$-0.01||-4.76%||2,427,562||$0.22||$0.22||$0.21|
|26 Nov 2021||$0.21||$-0.01||-4.55%||3,225,332||$0.23||$0.23||$0.21|
|25 Nov 2021||$0.22||$0.00||0.00%||2,021,213||$0.23||$0.24||$0.22|
|24 Nov 2021||$0.22||$-0.01||-4.35%||1,953,711||$0.23||$0.23||$0.22|
|23 Nov 2021||$0.23||$-0.01||-4.17%||1,923,632||$0.24||$0.24||$0.22|
|22 Nov 2021||$0.24||$0.01||4.26%||1,298,230||$0.24||$0.25||$0.24|
|19 Nov 2021||$0.24||$-0.01||-4.08%||1,066,940||$0.25||$0.25||$0.24|
|18 Nov 2021||$0.25||$-0.01||-3.92%||3,205,184||$0.25||$0.25||$0.24|
|17 Nov 2021||$0.26||$0.01||4.00%||650,719||$0.26||$0.26||$0.25|
|16 Nov 2021||$0.25||$-0.01||-3.85%||1,752,057||$0.27||$0.27||$0.25|
|15 Nov 2021||$0.26||$0.01||3.92%||2,641,125||$0.26||$0.27||$0.25|
|12 Nov 2021||$0.26||$0.01||4.00%||1,800,138||$0.25||$0.26||$0.25|
|11 Nov 2021||$0.25||$-0.01||-3.92%||1,897,488||$0.26||$0.26||$0.24|
|10 Nov 2021||$0.26||$0.00||0.00%||2,033,072||$0.26||$0.26||$0.25|
|09 Nov 2021||$0.26||$-0.01||-3.77%||2,016,164||$0.27||$0.27||$0.26|
|08 Nov 2021||$0.27||$-0.02||-7.14%||2,156,551||$0.28||$0.28||$0.26|
|05 Nov 2021||$0.28||$0.01||3.64%||872,704||$0.27||$0.28||$0.27|
|04 Nov 2021||$0.28||$-0.02||-6.78%||3,109,681||$0.30||$0.30||$0.27|
|03 Nov 2021||$0.30||$0.01||3.51%||1,641,995||$0.30||$0.30||$0.29|
|02 Nov 2021||$0.29||$-0.02||-6.67%||1,640,637||$0.30||$0.30||$0.29|
|01 Nov 2021||$0.30||$0.02||7.14%||4,386,909||$0.29||$0.31||$0.28|
|10 Dec 2020||Steven (Steve) Engle||Issued||2||$134,400||
Issue of options. As per announcement on 17/12/2020.
|10 Dec 2020||James Campbell||Issued||1||$64,000||
Issue of options. As per announcement on 17/12/2020.
|10 Dec 2020||Allen Ebens||Issued||1||$64,000||
Issue of options.
|10 Dec 2020||Steven Yatomi-Clarke||Issued||12||$825,600||
Issue of options.
|Dr James Campbell||Non-Executive Director||Nov 2014||
Dr Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies. Dr Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations. Dr Campbell sits on the Board of Australia's peak
biotechnology body, AusBiotech
|Mr Steven Yatomi-Clarke||Chief Executive OfficerManaging Director||Nov 2014||
Mr Yatomi-Clarke has over 17 years experience in investment banking specialising in healthcare and biotechnology, where he was consistently one of the most prolific and successful bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies. he He has the rare distinction of readily bridging the divide between science and commerce. Mr Yatomi-Clarke has also been a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy.
|Mr Steven (Steve) Barnard Engle||Non-Executive ChairmanNon-Executive Director||Nov 2014||
Mr Engle is the CEO of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Previously, Mr Engle served as CEO of Averigon, an advisory firm to the life science industry, as Chairman and CEO of XOMA, a developer of antibody therapeutics for metabolic, inflammatory, oncology and other diseases, and which had partnerships with multiple pharmaceutical companies, and as Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Steven Engle was VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. Mr Engle is a director on the board of AROA, a developer and marketer of regenerative products, and Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM. He was former director of Anthera Pharmaceuticals Inc.
|Dr Allen James Ebens||Non-Executive Director||Jun 2020||
Dr Ebens is Chief Science Officer at Vera Therapeutics, a San Francisco California based biotechnology company. Dr Ebens is a highly accomplished drug developer, having overseen the advancement of multiple successful drug development projects from concept to clinical development including polatuzumab, which is approved by the US FDA and is now marketed for use in diffuse large B-cell lymphoma. Dr Ebens was an early recruit to Juno Therapeutics (Juno), which is recognised as a one of the first CAR-T companies, and a leader in the successful and rapid clinical advancement of CAR-T cancer therapies. At Juno Dr Ebens was instrumental in establishing the scientific capabilities of the company in the emerging field of CAR-T. Previously, Dr Ebens held senior executive positions at global pharma and biotechnology leaders Genentech and Exelixis, where he worked from concept to clinic across multiple therapeutic platforms including targeted therapies, antibodies, antibody-drug conjugates, and T cell recruiting antibodies. He has also held roles in biotech companies including Bioseek and NGM Biopharmaceuticals.
|Ms Melanie Jaye Leydin||Company Secretary||Feb 2015||
|Melanie Jaye Leydin||Company Secretary||
|Mr David Kenley||14,200,000||2.22%|
|Mr Christopher Ferris||10,035,530||1.57%|
|Citicorp Nominees Pty Ltd||9,333,439||1.46%|
|Mr Anthony Shane Kittel & Mrs Michele Therese Kittel (Kittel Family Super A/C)||7,400,000||1.15%|
|Retzos Executive Pty Ltd (Retzos Executive S/Fund A/C)||7,300,000||1.14%|
|Mr Andrew Morrison Stewart||6,910,945||1.08%|
|Mr Richard Thomas Hayward Daly & Mrs Sarah Kay Daly (Daly Family S/ Tom A/C)||6,417,581||1.00%|
|Gavncath Pty Ltd (Shepherd Investment A/C)||5,550,000||0.87%|
|Dr Gavin James Shepherd & Mrs Catherine Shepherd (Tpj Superannuation Fund A/C)||5,450,000||0.85%|
|Mr David Kenley (Kenley Super Plan A/C)||4,525,264||0.71%|
|Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp)||4,028,419||0.63%|
|Cyl Trading Pty Ltd||4,000,000||0.62%|
|Dr Vincent William Fitzgerald & Mrs Penelope Fitzgerald (Fitzgerald Super Fund A/C)||3,909,090||0.61%|
|Jekl Holdings Pty Ltd (Kittel Property A/C)||3,500,000||0.55%|
|Est Mr Robert Steel Renton||3,224,246||0.50%|
|Milstein Investment Holdings Pty Ltd (Milstein Investment A/C)||3,022,593||0.47%|
|Wigtown Pty Ltd||3,009,261||0.47%|
|Boycecorp Pty Ltd (Boycecorp Discretionary A/C)||3,000,000||0.47%|
|Mr Raphael Johannes Veit||2,962,170||0.46%|
|The King'S Ransom (Vic) Pty Ltd (King Family Super Fund A/C)||2,750,000||0.43%|